ArticleBritish journal of pharmacology2009

Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.

Alison C MacKinnon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.